RE:RE:RE:RE:Interesting ! Enrique wrote...
"A while back Dr Kamat said we needed more data. At next round of official PH2 data, i hope we make headlines and Dr Kamat mentions us. It's no point talking efficacy data yet on such a small number of patients especially since initial group was undertreated IMO. But at least after 6-10 optimized treated patients or more, then there will be enough to talk about."
I agree Enrique. I think PDT is still viewed by many in the field to be this outlier Martian technology... but once we get more data in the optimally treated patients, & those patients get to longer median follow-up times (i.e. response data in a handful of patients at 12 months), we should get plenty of recognition in general.
Interestingly, the N-803 (Anktiva) + BCG combo therapy in high-risk BCG-unresponsive NMIBC patients didn't get any mention in that ASCO GU 2021 summary, & it has shown the most promise of all immunotherapeutics. An ongoing Ph 2 showed a 71% CR at any time based on a median follow-up of 10.7 months. They have projected a 40% CR at 12 months, & among responders, the estimated median duration of CR was ~19 months.
The above may be our future competition, but a 40% CR is certainly surmountable imo with our unique technology. Throw in our other advantages....fewer treatments/ease of delivery, improved chance for better compliance, likely lower cost, & our overall safety/positive side effect profile, we are very well-positioned to set a new treatment standard. JMHO. Let's preserve some bladders...